Randomized trials provide strong evidence regarding efficacy of interventions but are limited in their capacity to address potential heterogeneity in effectiveness within broad clinical populations. For example, a treatment that on average is superior may be distinctly worse in certain patients. We propose a technique for using large electronic health registries to develop and validate decision models that measure-for distinct combinations of covariate values-the difference in predicted outcomes among 2 alternative treatments. We demonstrate the methodology in a prototype analysis of in-hospital mortality under alternative revascularization treatments. First, we developed prediction models for a binary outcome of interest for each treatment. Decision criteria were then defined based on the treatment-specific model predictions. Patients were then classified as receiving concordant or discordant care (in relation to the model recommendation), and the association between discordance and outcomes was evaluated. We then present alternative decision criteria and validation methodologies, as well as sensitivity analyses that investigate 1) the imbalance between treatments on observed covariates and 2) the aggregate impact of unobserved covariates. Our methodology supplements population-average clinical trial results by modeling heterogeneity in outcomes according to specific covariate values. It thus allows for assessment of current practice, from which cogent hypotheses for improved care can be derived. Newly emerging large population registries will allow for accurate predictions of outcome risk under competing treatments, as complex functions of predictor variables. Whether or not the models might be used to inform decision making depends on the extent to which important predictors are available. Further work is needed to understand the strengths and limitations of this approach, particularly in relation to those based on randomized trials.
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Translation of mechanistic knowledge acquired from randomized trials into effective treatment strategies for individual patients is critical for achieving improvements in health. Comparative effectiveness research 1 aimed at identifying the clinical and environmental conditions where interventions are most likely to work can help to ensure successful translation. Methodological development for performing comparative effectiveness research is ongoing. A common approach is to stratify the sample and estimate group-level treatment effects within various subpopulations, but in practice, it is often not possible to study even a small fraction of the potentially relevant subgroups due to reduced power. Analyses that are specific to distinct combinations of diseaserelated characteristics and patient comorbidities can potentially provide more accurate representations of treatment benefit. However, it remains unclear which statistical techniques are most appropriate for patient-centered outcomes research. 2 Our primary goal was to propose a practical and empirical technique for building and validating clinical decision models that 1) recommend 1 of 2 (or more) competing treatment alternatives that will optimize the predicted outcome; 2) estimate the relative odds of outcome under competing treatments, given a specific combination of input variables; and 3) evaluate existing clinical decision-making practices against the recommendations set forth by the model. We believe our methodology may help in identifying potential pathways and barriers to treatment effectiveness, stimulating further research.
We chose the decision between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) with respect to minimizing risk of postoperative in-hospital mortality as a motivating setting. The choice between these 2 procedures for a given patient is nuanced and involves consideration of both risk factors and various aspects of their cardiovascular disease. Current guidelines set forth by joint task forces involving the American College of Cardiology Foundation and the American Heart Association 3,4 as well as the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery 5 reflect this complexity and may therefore be difficult to incorporate into individual practice. Furthermore, the guidelines are based mostly on population-level comparisons without consideration of individual treatment effects (although guidelines for certain subpopulations such as those with end-stage renal disease or type II diabetes mellitus have been incorporated).
The purpose of our decision modeling presentation is to better describe the underlying methodology, not to inform actual health care decisions. Although in-hospital mortality is an important consideration for patients undergoing revascularization, it is but one component of a complex risk profile, and the decision should incorporate all these risks.
MODELING METHODOLOGY
We consider the decision between two competing treatments; extensions to 3 or more competing treatments are straightforward. While we consider only binary outcomes in this article, the methodology could be modified to accommodate continuous and time-to-event outcomes.
Our modeling approach incorporates 2 phases: development (phase I) and validation (phase II). In the development phase, separate, treatment-specific prediction models for an adverse outcome of interest such as mortality are established and calibrated. We then define decision criteria and related measures, proposing 3 possible approaches: 1) binary recommendation of the treatment for which predicted probability of the undesired outcome is minimized; 2) definition of a decision model odds ratio, equal to the predicted odds of the outcome under one treatment divided by the predicted odds of the outcome under the competing treatment (or, alternatively, a risk ratio equal to the ratio of predicted probabilities); and 3) definition of a small number of categories based on the models' predicted probabilities and the decision model odds ratio. In the validation phase, a new data set is used to compare recommendations from the models against observed decisions made in the standard process of care. As we detail later, one proposed validation technique is to evaluate the association between discordance (patients given the opposite treatment of that recommended by the model) and outcome. We also propose a calibration analysis for the decision model odds ratio and sensitivity analyses investigating the potential effects of imbalance on covariates between treatments and the potential (aggregate) effects of unobserved covariates on decision model odds ratio estimates.
Data Considerations
We analyzed data on 586,754 hospital inpatient discharges who had either PCI or CABG as their primary procedure. These data were extracted from the following 2009 to 2011 US Agency for Healthcare Research and Quality State Inpatient Databases: Arizona, California, Florida, Iowa, Maryland, Michigan, and New Jersey. For the purposes of inclusion in the study, discharges with an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) primary procedure code of 36.1x (bypass anastomosis for heart revascularization) were considered CABG discharges, while discharges with an ICD-9-CM primary procedure code of 36.09 (coronary angioplasty not otherwise specified) or 00.66 (percutaneous transluminal coronary angioplasty or coronary atherectomy) were considered PCI discharges.
As our proposed models are intended for application in large and diverse population registries, we felt that random data partitioning provided the most straightforward way to implement the proposed decision modeling procedure; however, cross-validation or bootstrap resampling with out-of-sample test error estimation 6-8 could in principle be used. For our prototype analysis regarding the decision between PCI and CABG, the discharge records under each treatment were randomly divided into 3 data sets prior to modeling. The first 2 data sets were used for development (50% of that treatment's discharge records) and calibration (25% of that treatment's discharge records) of that treatment's probability model for inhospital mortality, respectively (phase I). The remaining 25% of the discharge records were allocated to a (combined) validation data set to evaluate outcomes as they relate to model recommendations and actual treatments administered (phase II).
Phase I: Model Development
For each given treatment, we developed a probability model for the outcome using the treatment's model development data set. Specifically, we obtained the following functions expressing the estimated probability of outcome given a set of covariates: In these equations, Y is an indicator variable for the outcome, X is a vector of input variables (or covariates), and T is a treatment indicator (e.g., T 5 1 for PCI and T 5 2 for CABG). A standard approach for building these probability models is multivariable logistic regression, although other predictive modeling algorithms such as random forests 9 or elastic net 10 could be used. In our PCI v. CABG example, we used elastic net logistic regression to estimate each of the 2 probability functions.* Elastic net works by purposely biasing (''shrinking'') regression coefficients toward zero; coefficients for variables not independently associated with the outcome are shrunken all the way to a value of zero (to implement variable selection), while coefficients for correlated predictors are averaged together (to prevent the adverse effects of multicollinearity on precision of coefficient estimates). Considered as predictors for these models were age, sex, and the set of present-on-admission ICD-9-CM diagnosis codes for each patient. As ICD-9-CM diagnosis codes are very detailed and involve over 14,000 separate categories, we hierarchically aggregated them by truncating trailing digits from sparsely represented codes. Truncation of the fifth and subsequently the fourth digit from a given code occurred when that code was represented by fewer than 500 patients in the overall data set (prior to partitioning). This method, which is described in detail elsewhere, 11 resulted in 747 distinct diagnosis-related predictors that were considered for each of the 2 treatment-specific elastic net logistic regression models. Thirty predictors were selected for the CABG model, and 68 were selected for the PCI model. Odds ratio parameter estimates from the 2 models are presented in Figure 1 .
A common graphical method for evaluating the calibration of probability models is to plot the observed incidence of the outcome as a function of the model-predicted probability. 12 However, these methods only indicate lack of fit, as opposed to remedying miscalibration. Recently, we proposed a flexible modeling technique for bias-correcting (or recalibrating) clinical prediction models. 13 We used this method to recalibrate both the CABG and PCI probability models. Restricted cubic splines (with 2 knots) were incorporated to model nonlinearities in the calibration curves. Details of the calibration * Algorithmic details of the elastic net modeling procedure are as follows: a mixing parameter-that is, the proportion of elastic net penalty term dedicated to the L 1 (lasso) term, as opposed to the L 2 (ridge) term-of a 5 0:90 was chosen for the CABG model, and a mixing parameter of a 5 0:85 was chosen for the PCI model based on minimization of the model goodness-of-fit criterion via cross-validation. The model shrinkage parameter l was chosen as the largest value for which cross-validated prediction error was not more than 1 standard error greater than that observed for the value of l that minimized crossvalidated prediction error. Odds ratio estimates for in-hospital mortality for both the coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) prediction models, based on elastic net logistic regression. Results sorted by ascending odds ratio estimate under the PCI model, which included 68 variables; the CABG model included 30 variables. The plot excludes estimates relating to palliative care due to space issues; this predictor was selected for both prediction models and the estimated odds ratio was 102 for the CABG model and 32 for the PCI model. MI, myocardial infarction. procedure for the individual probability models are given in online Appendix 1 (available at http:// mdm.sagepub.com/supplemental).
Calibration for each of the 2 models was generally good and improved upon model recalibration ( Figure  2 ). Discrimination of the CABG model was moderate (concordance index, or C-statistic, of 0.77), and discrimination of the PCI model was good (C = 0.91).
Decision Criteria and Related Measures
Next, we detail the 3 possible approaches mentioned above for describing the multiple predicted outcomes among competing treatments.
Binary Recommended Treatment
In the first approach, the recommended treatment for a patient with given values of the predictor variables is simply the one for which the predicted probability of the outcome is lower. y While this approach ignores quantifications of absolute and relative risk derived from each treatment-specific model, a binary recommendation for 1 of the 2 competing treatments is the easiest to interpret and allows for straightforward analyses of observed v. model-recommended decisions.
With this approach, we can define concordant and discordant treatments as follows: let R i and O i represent the model-recommended and observed treatment for patient i in the validation data set, respectively. A concordant treatment is one for which O i 5 R i ; likewise, a discordant treatment is one for which O i 6 ¼ R i . We use the symbol D i to represent discordance; that is,
For our PCI v. CABG analysis, we found that, among the 146,753 discharges in the validation data set, 9304 (6.3%) were recommended for CABG and 137,449 (93.7%) were recommended for PCI. Overall, there were 39,039 discordant discharges (26.6% of those in the validation data set). Discordance was observed for 7838 of 9304 (84.2%) of those recommended for CABG and 31,201 of 137,449 (22.7%) of those recommended for PCI.
The incidence (Bonferroni-adjusted 95% confidence interval) of in-hospital mortality was 0.68% (0.62%-0.74%) among concordant discharges and 2.8% (2.6%-3.0%) among discordant discharges, corresponding to an odds ratio (95% confidence interval) of 4.2 (3.8-4.6) . That is, the odds of mortality were approximately 4 times greater among discordant discharges than among concordant discharges.
Decision Model Odds Ratio
In the second approach, a covariate-specific decision model odds ratioû i (where the subscript i indexes observations in the validation data set) is defined as follows:
Alternatively, this may be expressed as a risk ratio (ratio of probabilities); however, an advantage of using the odds ratio formulation is that it more readily allows assessment of calibration (see ''Phase II-Model Validation'' below). When absolute risks are low, as in the case of many clinical end points, the odds ratio and risk ratio are close to one another.
Other Approaches
The decision model odds ratio is a relative quantity; when absolute risks are clinically low, a ratio very different from 1.0 might not represent meaningful absolute differences in likelihood of outcome. In light of this, we describe a third approach whereby a set of discrete strata is defined according to the values ofp 1 ð Þ X i ð Þ,p 2 ð Þ X i ð Þ, andû i . For example, the following strata were prespecified for our PCI v. CABG example (see Figure 3 ): 1 . low risk, defined as bothp 1 ð Þ X i ð Þ\0:005 and p 2 ð Þ X i ð Þ\0:005; 2. large predicted benefit under CABG, defined as not low risk withû À1 i .2:0; 3. small predicted benefit under CABG, defined as not low risk with 1:3\û À1 i 2:0; 4. equivocal risk, defined as not low risk with each model's probabilities within 630% of one another, that is, 1:3 À1 û i \1:3; 5. small predicted benefit under PCI, defined as 1:3 û i \2:0; and 6. large predicted benefit under PCI, defined asû i ! 2:0:
Choice of the thresholds that govern assignment to these strata is subject to interpretation and should represent clinically meaningful values. Table 1 contains results of this stratified analysis. Most cases (53.4%) were predicted to have large benefit under PCI relative to CABG (category 6 above). In this group, there was a 23.8% discordance rate; that is, 23.8% of patients received CABG despite the large predicted benefit of PCI. These patients were 3.2 y We assume here and throughout the rest of the article (without loss of generality) that the outcome is undesired, and as such, lower probabilities of the outcome are better.
(95% CI, 2.6-3.9) times more likely to die in the hospital than patients receiving concordant PCI treatment. The next largest category was those at low predicted risk under both treatments (category 1 above). Even though absolute risk in this group was low, with mortality of 0.4% for patients receiving CABG and 0.1% for patients receiving PCI, discordance was still associated with an odds ratio for inhospital mortality of 3.5 (1.9-6.5). Those at equivocal levels of predicted risk under each treatment did not indicate significantly different odds of mortality (odds ratio, 1.2; 95% CI, 0.9-1.6).
Finally, direct evaluation of the vector of probabil-
i is straightforward and may be appealing for applications in which patients are heterogeneous with respect to both absolute and relative risk measures under each treatment.
Phase II-Model Validation
In the context of our proposed methodology, model validation generally entails the comparison of actual decisions made during the course of care to predictive information given by the decision model, whether the predictive information is given in the form of a recommended treatment, a decision model odds ratio, or a risk stratum.
The (global) effect of discordance is then defined as the odds ratio for the outcome comparing discordant decisions to concordant decisions. This can be estimated using a standard logistic regression model; furthermore, hypotheses involving variations in the incidence of discordance and variations in the discordant-to-concordant odds ratio for outcome across subpopulations can be studied by incorporating covariates into this logistic regression model. A simple extension to this logistic model that incorporates a main effect term for discordance, a main effect term representing the various risk strata, and their interaction allows the estimation of strata-specific discordant-to-concordant odds ratios such as the ones we present in Table 1 . We estimated both global and stratum-specific effects of discordance for our PCI v. CABG analysis using the combined validation data set. Key to validating the decision model odds ratioû i is addressing the question of whether the increment (or decrement) in odds described by the metric actually holds when the discordant treatment is administered. In other words, we evaluate the relationship between the decision model odds ratioû i and the outcomes of discordant treatment. We propose a technique for evaluating the calibration of the decision model odds ratiô u i within the validation data set, using an analysis akin to the recalibration methods we described previously. 13 The goal is to generate a calibration curve that allows for graphical assessment against the horizontal line given at y 5 0, which represents perfect calibration ofû i . The required derivations for producing this curve are given in online Appendix 1 and Appendix 2 (available at http://mdm.sagepub.com/supplemental). We used a 3-knot cubic spline logistic regression model based on our PCI v. CABG validation data set to assess calibration of the decision model odds ratioû i Calibration of the discordant-to-concordant odds ratioû i was generally good (Figure 4 ). Slight miscalibrations for extremely high odds ratios (i.e., odds ratios greater than 10) were suggested by the curve. These miscalibrations were not large enough to switch the recommended treatment and could have simply been the result of estimation issues in the tail of the spline curve.
It is also important to consider the potential impact of the model at the population level. Whereas in some cases, the mortality reduction is clinically inconsequential for individual patients, applications to populations of patients may introduce meaningful reductions in ''statistical lives.'' 14 For instance, approximately 1 million revascularization procedures occur annually in the United States. 15 We estimated expected mortality per 1 million patients treated under 2 scenarios: 1) assuming the proportion of patients within each risk stratum administered each procedure is equal to that observed in our randomly selected test data set and 2) assuming patients are treated according to the model recommendation. Results, which are displayed in Table 2 , suggest that ''statistical averted mortality''-defined in this case as the potential number of in-hospital deaths avoided when decisions are all concordant with the model recommendation-might be as high as 3000 to 4000 deaths per annum in the United States.
Sensitivity Analyses

Influence of Covariates on Treatment Selection
Our proposed decision modeling methodology works by creating 2 multidimensional functions relating patient characteristics to the predicted probability of outcome-one function for CABG and another for PCI. When decisions systematically occur in response to patients' comorbid status, estimation may be inaccurate due to nonoverlap in covariate distributions. To evaluate this phenomenon, we conducted a sensitivity analysis, which first estimated propensity scores (defined as each patient's probability of receiving CABG given the values of their baseline covariates) and then evaluated performance of the decision model as a function of the propensity score. The propensity score model was estimated using the combined training data set and applied to the observations in the validation data set for analysis. Then, using the validation data set, we estimated the overall discordant-to-concordant odds ratio as a function of the propensity score using cubic spline logistic regression. Discordant v. concordant odds ratios compare, within each stratum, patients who were administered the treatment with higher predicted in-hospital mortality (either PCI or CABG) to patients who were administered the treatment with lower predicted mortality. CABG, coronary artery bypass grafting; CI, confidence interval; PCI, percutaneous coronary intervention. a Assumes that the patient is not low risk.
The observed C-statistic for the propensity modelapplied to the observations in the validation data set-was 0.77, indicating moderate ability of the observed baseline covariates to predict observed treatments. Propensity scores overlapped substantially ( Figure 5 ), ranging between 0.1% and 99.9% for patients treated with CABG and ranging between \0.1% and 99.8% for patients treated with PCI. The discordant-to-concordant odds ratio was greatest among patients with low propensity scores (i.e., those whose covariates predicted that they were likely to receive PCI) and gradually declined as the propensity score increased. Based on the pointwise confidence interval estimates of the curve, the odds ratio remained significantly greater than 1 for all whose propensity scores were less than 0.64, which amounted to approximately 97% of cases in the validation cohort.
Major Unobserved Covariates
Another sensitivity analysis was carried out to evaluate the potential effect of an unobserved binary covariate on the results. The occurrence of this unobserved covariate, which we denote asX, was assumed to be independent of the observed covariates in the analysis. Likewise, the effect ofX on the predicted odds of in-hospital mortality under each treatment's model-which we represent using an odds ratio z CABG for the CABG model and an odds ratio z PCI for the PCI model-was assumed to be independent from the effects of the observed covariates. These independence assumptions had the effect of representing the effect of the unobserved variable as a worst-case scenario, since correlation between assignment tõ X 5 1 (presence ofX) and observed covariates as well as correlation between the effects ofX and the effects of observed covariates would lessen impact.
For example, suppose a patient was predicted to have a probability of in-hospital mortality under CABG of 10% (odds of 0.1 O 0.9 = 1/9) and a predicted probability under PCI of 5% (odds of 1/19). If the covariateX is present (X 5 1) and the adjustment factor for CABG is z CABG 5 1=2, then the updated odds of in-hospital mortality given the presence of the unobserved covariateX are (1/9)(1/2) = 1/18. Converting the updated odds back to the probability scale (using the formula probability 5 14 1 1 odds À1 Â Ã ), we find that the updated probability under CABG is approximately 5.3%. A similar calculation for PCI assuming z PCI 5 2 in this hypothetical patient results in an updated probability under PCI of 9.5%. Thus, for this patient, the recommended treatment is switched from PCI to CABG, which (given his or her actual treatment) switches his or her discordance status under the decision model.
From the above notation and corresponding example, we note that evaluation of both the effect of the unobserved covariate on individuals undergoing CABG (z CABG ) and the effect of the unobserved covariate on patients undergoing PCI (z PCI ) can be simplified by studying their ratio (i.e., g 5 z CABG 4z PCI ). Here, the parameter g is interpreted as the differential effect of the missing covariate between the 2 treatments; when g 5 0:5, the missing covariate is assumed to affect in-hospital mortality twice as severely among patients undergoing PCI than among patients undergoing CABG, and the converse is true when g 5 2.
Using the validation data set, we conducted a Monte Carlo simulation that generated repeated data sets, randomly assigning patients to haveX 5 1 in each data set. Ten thousand data sets were generated, each incorporating a randomly chosen prevalence value forX (based on the random uniform Figure 4 Calibration curve for the decision model odds ratioû. Values ofû greater than 1 suggest that the odds of in-hospital mortality under coronary artery bypass grafting (CABG) areû times greater than the odds under percutaneous coronary intervention (PCI), and values ofû less than 1 suggest the odds under PCI arê u À1 times greater than the odds under CABG. Perfect calibration is indicated by the horizontal line given at y = 0. Shaded bands represent pointwise 95% confidence intervals. The observed-toexpected (O/E) ratio plotted on the y-axis can be interpreted as follows: an O/E ratio of 0.5 implies that true odds of in-hospital mortality among discordant patients was half of that described by the decision model odds ratioû. For instance, whenû 5 10, the calibration model indicated an O/E ratio of approximately 0.8; thus, the true increase in odds associated with discordant decisions was a factor of 8 instead of a factor of 10. distribution). To each simulated data set, we applied a series of differential effect parameters ranging from g 5 1=4 to g 5 4; for each differential effect parameter, we then reestimated the discordant-to-concordant odds ratio. Results of these manipulations on the overall discordant-to-concordant odds ratio estimate were then visualized.
Results of this Monte Carlo analysis, summarized in Figure 6 , indicate that the discordant-to-concordant odds ratio was robust to even highly prevalent unobserved variables with strong differential effects; for example, a highly prevalent missing covariate with a 4-fold differential effect between patients undergoing CABG and patients undergoing PCI did not qualitatively degrade the overall discordant-toconcordant odds ratio, with mortality being twice as likely among discordant discharges than among concordant discharges.
DISCUSSION
We propose a straightforward technique for measuring predicted benefit of undergoing a particular treatment relative to a comparator treatment, with respect to optimizing risk for a single outcome of interest. At its core, the procedure entails developing prediction models for each treatment that map distinct combinations of covariate values to a predicted probability of outcome and deriving measures of evidence based on the relative values of the probability estimates. We also propose techniques for validating the model, including estimating the effect on outcome of clinical discordance to a model-based decision rule.
It is the rare patient who is ''average'' and can thus be expected to have outcomes matching those reported in clinical trials. Instead, individual patients vary widely with respect to genetic, environmental, and behavioral features. Nonetheless, the best current ''evidence-based'' approach to clinical care would prompt clinicians to make care decisions on the basis of population-average results of related clinical trials. The trouble is that decisions based on population averages may well be wrong for many individual patients. The importance of our approach is that it incorporates more information than clinical trial averages and may thus produce superior recommendations for individuals. In an example analysis of the decision between PCI and CABG, we showed that discordance in treatment selection from the model recommendation was associated with 4.5 times the odds of in-hospital mortality than concordance.
On the other end of the spectrum, the potential outcome for a specific patient under 2 competing treatments 16 is clearly not directly observable since only Figure 5 Results of our first sensitivity analysis, which evaluated potential effects of imbalanced covariates between observed treatments. Propensity scores (i.e., predicted probability of receiving coronary artery bypass grafting [CABG] based on each patient's combination of baseline characteristics) were estimated for each of the discharges in the validation cohort. In the figure, histograms describing each (actual) treatment group's propensity score distribution underlie a plot of the estimated overall discordant-to-concordant odds ratio v. propensity score. The curve indicates that, for all patients with propensity scores less than 0.64-approximately 97% of cases in the validation cohort-discordance was still associated with increased odds of in-hospital mortality. On the other hand, the decision model may not be appropriate for certain patients strongly indicated for CABG (i.e., those with propensity scores .0.64).
Figure 6
Results of our second sensitivity analysis, which evaluated the impact of an unobserved covariate on the overall discordant-to-concordant odds ratio estimate. Ten thousand data sets were generated, each a copy of the original validation data set with the unobserved covariateX randomly assigned to be present or absent among all patients. The prevalence ofX 5 1 was set for each data set by drawing from a random uniform distribution. For each data set, the discordant-to-concordant odds ratio was recalculated by assuming varying values for the differential effect of the treatment on in-hospital mortality between patients undergoing coronary artery bypass grafting (CABG) and patients undergoing percutaneous coronary intervention (PCI) (parameter g). Panel (a) displays a scatterplot of individual simulation results for 5 sample values of g v. the randomly assigned prevalence value for the unobserved covariate. Panel (b) displays a smoothed (via thin-plate regression splines) contour plot of the 3-dimensional surface describing the estimated odds ratio as a function of both g and the randomly assigned prevalence value. The lines in the contour plot, which are labeled in the figure, represent constant levels of the 3-dimensional odds ratio surface. one treatment can be administered and the patient experiences only one outcome. While our methodology cannot directly compare 2 potential outcomes for a single individual, it does provide an independent prediction of the outcome under each of the treatments for distinct combinations of predictor values. This is more flexible than other proposed methods that stratify patients according to predictions of absolute risk reduction but nonetheless assume consistent relative effects across the population. 17 Our methodology also provides a mechanism for directly assessing the effects of observed medical decisions in patient-specific care interactions, relative to decisions that are informed by an empirical prediction modeling algorithm. We hypothesize that the efficiency and accuracy with which medical decisions are made are unlikely to be uniform across diverse patient populations. In situations where discordance is associated with increased risk of poor outcomes, certain subpopulations could experience greater discordance and therefore higher risk than other subpopulations (i.e., minorities, patients treated at institutions with poorer quality of care). Modifying the stratum-specific discordant-to-concordant odds ratio model described above (specifically, by replacing the stratification variable with relevant patient and/or hospital characteristics) can allow for analyses seeking to identify these subpopulations, thus providing a necessary framework for studies involving heterogeneity in the quality of decision making.
Decisions in health care are frequently made with respect to multiple end points. While this proposed decision modeling technique only supports the analysis of a single outcome, developing models for the most clinically important end point might nonetheless help inform processes of care and associated decision-making practices. Further methodological development will be necessary to enable extensions into situations with multiple outcomes.
We present multiple analyses to compare predicted risk of outcomes under 2 competing treatments: binary recommended treatment, discrete risk strata, decision model odds ratio, and finally direct interpretation of the vector of probability estimates. The latter is perhaps the most direct and allows for the interpretation of absolute risks under competing interventions. 18, 19 The other 3 pertain to relative measures of risk; while these may be less appealing than absolute risk measures for clinical applications, they do allow for various validation analyses, such as assessments of concordant v. discordant care and our proposed calibration analysis for the decision model odds ratio.
Like all observational studies, controlling for the independent effects of unobserved variables here is impossible. Our proposed decision modeling approach therefore cannot evaluate causality. Furthermore, the accuracy of the methodology relies on the availability of relevant predictors. In this article, we proposed methodology for conducting a Monte Carlo analysis to assess the sensitivity of the results to a major unobserved covariate. For this particular analysis that investigated decisions among revascularization procedures, even a highly prevalent predictor that is independent of the other baseline characteristics in the model and that has a 4-fold differential effect between patients undergoing CABG and patients undergoing PCI did not qualitatively degrade the overall discordant-to-concordant odds ratio.
An interesting aspect of our methodology is that, unlike standard analyses of average treatment effects, bias in either the model-based decision rule or the discordant-to-concordant odds ratio due to imbalances on observed predictors is not an issue, so long as the model has been correctly specified. This is because the model estimates are conditional (made with respect to distinct combinations of predictor values), rather than marginal (made across fixed and arbitrary values of predictor values). However, the issue of imbalance on observed predictors is distinct from the issue of lack of representation (i.e., lack of overlap). This especially occurs in observational data where decisions are systematically related to the available predictor variables. We proposed an examination of propensity score distributions to evaluate the extent to which decisions are determined by observed covariates; in our particular analysis of revascularization procedures, a sizable degree of heterogeneity in decision making was observed, with the 2 treatments' propensity score distributions overlapping one another and extending over wide ranges. Nonetheless, full consideration of unavailable predictors is important for gauging the model's clinical usefulness; in our example model for revascularization, we did not have information on anatomical characteristics. Like any prediction model, extrapolation of the decision model into areas of the covariate space not supported by the data risks potential bias and greater uncertainty. Research into methods for describing extrapolation of the decision model and evaluating when predictions should or should not be made is needed. When practical decisions can be made to restrict study inclusion criteria to the subpopulation of patients for whom there is heterogeneity in decision making, such restrictions are recommended since they help to maximize overlap in covariates between patients receiving each treatment. In addition, we recommend that these techniques should only be applied to large health data registries, so that overlap in populations and precision of underlying prediction models are maximized. Finally, our method assumes that the prediction problem is static in nature; extensions to time-dependent settings would require consideration for potential biases due to time-varying covariates.
Analyses using randomized data can overcome many of the aforementioned issues. However, since the size of randomized clinical registries is typically determined by an analysis of power for the average treatment effect, they are rarely large enough to construct subgroup analyses, 20 let alone a full prediction analysis that evaluates outcomes of alternative treatment decisions relative to patients' individual characteristics. An exception is with revascularization: the SYNTAX score II 21 incorporated both anatomical characteristics (as represented by the original SYN-TAX score) 22, 23 and clinical characteristics. Model development was based on randomized data from 1800 patients, and 7 clinical predictors that exhibited both significant main effects (a = 0.05) within procedure-specific models and a significant 2-way interaction (a = 0.10) with the randomized CABG/ PCI treatment in the combined cohort were included in the model. This analysis was clearly unique and innovative, representing a step beyond existing models in cardiac surgery (e.g., EuroSCORE, 24 Society of Thoracic Surgeons' Predicted Risk of Mortality [http://riskcalc.sts.org], Wu's score for mortality after PCI, 25 etc.), which only predict outcomes (under a chosen treatment). However, the extent to which model performance might be improved with an even larger data set-one that could support more complex interactions among a greater number of predictors-is unknown. Since acquiring randomized data on such a large sample is often prohibitively expensive, we feel that our approach may be a useful covariate-specific analogue to well-controlled (e.g., propensity-matched) observational studies evaluating average treatment effects.
Methodologically, we propose the development of separate prediction models within each treatment as opposed to a single interaction model that (implicitly) assumes the same predictors are used for modeling both treatments. This departs from prior efforts such as the SYNTAX score II. Different mechanisms might plausibly influence mortality risk under CABG than those that influence it under PCI (e.g., deep sternal wound infection is a risk with CABG 26 but not with PCI). While the interaction approach can handle this situation simply by assigning coefficients near zero, the use of separate models allows for the application of modern feature selection routines such as lasso/elastic net shrinkage and random forests within each treatment. As we mentioned earlier, however, our model for revascularization was strictly to facilitate descriptions of the proposed methodology and comparisons with existing approaches.
In summary, we propose a practical technique for developing and validating empirical decision models using large health care data registries. The technique can be especially useful in assessing observed clinical treatments against model-recommended treatments. Further research will be necessary to evaluate the utility of these models for informing actual patient care decisions-especially when they are derived using large observational data sets, since the possibility of residual confounding due to lack of important predictors can never be fully excluded.
